智通财经APP获悉,2月20日,百时美施贵宝(BMY.US)宣布了3期临床试验CheckMate‐816的最终总生存期(OS)分析结果。该研究评估了其重磅PD-1抑制剂Opdivo(nivolumab)联合含铂双药化疗,作为可切除非小细胞肺癌(NSCLC)成年患者的新辅助治疗的效果。结果显示,与仅接受新辅助化疗相比,Opdivo组合在总生存期这一关键性次要终点方面具有统计学显著且具有临床意义的改善...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.